https://www.selleckchem.com/products/TW-37.html
The rate of complications between the groups was similar (RR 0.87 [0.33, 2.29], P = .77; I 2 0%). In the subgroup analysis of paroxysmal AF, RDN + PVI was shown to reduce AF recurrence (RR 0.64 [0.49, 0.82], P less then .001; I 2 0% and HR 0.56 [0.38, 0.82], P = .003; I 2 0%) compared to PVI alone. RDN + PVI has a moderate certainty of evidence in the reducing AF recurrence with an absolute reduction of 197 fewer per 1000 (from 254 fewer to 124 fewer). Conclusion RDN in addition to PVI, is associated with reduced 12-month AF recurrence an
Gefällt mir
Kommentar
Teilen
